Bio-Techne Shareholders Approve Merck KGaA Acquisition, Clearing Path to Life Sciences Integration

The Quick Take

• Bio-Techne shareholders voted overwhelmingly to approve the acquisition agreement with Merck KGaA at a special meeting
• The approval paves the way for Bio-Techne to become a wholly-owned Merck KGaA subsidiary with regulatory approvals remaining
• Merck KGaA gains Bio-Techne's protein and antibody portfolio, strengthening its Life Science tools and reagents segment

Bio-Techne Corporation shareholders approved the company's acquisition agreement with Merck KGaA, the German science and technology conglomerate, at a special meeting convened to vote on the transaction. The overwhelming shareholder support — described in company filings as strong — clears the path toward completing the acquisition and Bio-Techne transitioning to a wholly-owned Merck KGaA subsidiary. Bio-Techne, traded on Nasdaq under the ticker TECH, is a life science research tools company specializing in proteins, antibodies, immunoassays, and cell biology reagents used in academic and pharmaceutical research. The acquisition represents Merck KGaA's strategic commitment to strengthening its Life Science segment with Bio-Techne's differentiated reagent portfolio.

Merck KGaA's Life Science segment competes with major research tools providers including Thermo Fisher Scientific, Danaher's life sciences platforms, and Agilent Technologies. Acquiring Bio-Techne provides specific protein and cytokine product lines that have demonstrated strong academic and pharmaceutical industry adoption, filling portfolio gaps in their existing biologics characterization and cell culture toolkit. For Bio-Techne shareholders, the acquisition delivers a premium over pre-announcement trading prices that compensates for the transition from independent public company status. Institutional shareholders with governance mandates requiring continued independent operation will exit their positions upon transaction completion.

Remaining closing conditions include regulatory approvals from competition authorities in jurisdictions where both Merck KGaA and Bio-Techne generate significant revenue — the EU and US are the primary regulatory venues requiring antitrust review. The timeline from shareholder approval to closing depends on regulatory review duration, which for life science tools acquisitions has historically ranged from two to six months. Research institution customers and ongoing Bio-Techne sales relationships will be monitored for any disruption during the integration transition, as customer retention is a key value preservation metric for Merck KGaA in managing the acquired business post-close.

Synthesized from 1 source.